Skip to main content
SpringerLink
Log in

Management of hepatic metastases from colorectal cancer: Systemic chemotherapy

  • Subject Review
  • Published:
Journal of Gastrointestinal Surgery

Abstract

The current phase III studies of chemotherapy in advanced colorectal cancer include 60% to 85% of patients with the liver as a site of metastatic disease. Within the past 10 years, various modulatory combinations of 5-fluorouracil (5-FU) with agents such as leucovorin, interferon, N-(phosphonacetyl)-L-aspartate (PALA), and methotrexate have produced higher response rates than 5-FU alone. A major sevenarm study, conducted by the Southwestern Oncology Group and reported in 1995, suggested that singleagent, continuous-infusion 5-FU demonstrated the most encouraging results. Nine of 12 reported randomized studies comparing the combination of 5-FU and leucovorin with 5-FU alone report significant increases in response rates; two studies reported significant increases in survival. The meta-analysis project involving 1381 patients confirmed the increase in response rate with the combination (23%) vs. 5-FU alone (11%) but did not demonstrate any significant difference in median survival. The current issues involving 5-FU administration largely concentrate on the best approach (modulation vs. scheduling) and comprehensive evaluation of end points (quality of life, survival, and pharmacoeconomics). The current literature examining quality-of-life issues suggests that 5-FU and low-dose leucovorin produce the best overall improvement in symptoms. Others argue that continuous-infusion scheduling is also associated with a very good quality of life (although the increased cost and morbidity of continuous-infusion administration has to be factored into this consideration). An important phase III study is currently being conducted by the national Cancer Institute of Canada comparing immediate vs. delayed (until symptomatic) chemotherapy in patients with advanced colorectal cancer. Of the new approaches to therapy, perhaps the most immediately applicable are the new thymidylate synthase inhibitors (in patrticular, Tomudex, which produces a response rate equivalent to that of 5-FU plus leucovorin with less toxicity and a more convenient schedule).

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Cohen AM, Minsky BD, Schilsky RL. Colon cancer. In DeVita VT Jr, Hellman S, Rosenberg SA eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia: JB Lippincott, 1993, pp 929–977.

    Google Scholar 

  2. Pinedo HM, Peters GFJ. Fluorouracil: Biochemistry and pharmacology. J Clin Oncol 1988;6:1653–1664.

    PubMed  CAS  Google Scholar 

  3. Einhorn LH. Improvements in fluorouracil chemotherapy? J Clin Oncol 1989;7:1377–1379.

    PubMed  CAS  Google Scholar 

  4. Kemeny N. Chemotherapy for colorectal carcinoma: One small step forward, one step backward. J Clin Oncol 1995;13:1287–1290.

    PubMed  CAS  Google Scholar 

  5. Borner MM. More is not always better: A case for low-dose, leucovorin. J Clin Oncol 1993;11:382–383.

    PubMed  CAS  Google Scholar 

  6. Moertel CG. Large bowel. In Holland JF, Frei E, eds. Cancer Medicine. Philadelphia: Lea & Febiger, 1973, pp 1497–1626.

    Google Scholar 

  7. Conti JA, Kemeny NE, Saltz LB, Andre AM, Grossano DD, Bertino JR. Continuous infusion fluorouracil/leucovorin and bolus mitomycin-C as a salvage regimen for patients with advanced colorectal cancer. Cancer 1995;75:769–773.

    Article  PubMed  CAS  Google Scholar 

  8. Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A, MacDonald JS. Phase II study of fluorouracil and its modulation, in advanced colorectal cancer: A Southwestern Oncology Group study. J Clin Oncol 1995; 13:1303–1311.

    PubMed  CAS  Google Scholar 

  9. Advanced Colorectal Cancer Meta-Analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate. J Clin Oncol 1992;10:896–903.

    Google Scholar 

  10. Advanced Colorectal Cancer Meta-Analysis Project. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer. J Clin Oncol 1994;12:960–969.

    Google Scholar 

  11. Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich L, Mittleman A. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 1987;5:1559–1565.

    PubMed  CAS  Google Scholar 

  12. Petrelli N, Douglass H Jr, Herrera L, Russell D, Stablein D, Bruckner H, Mayer R, Schinella R, Green M, Muggia F, Megibow A, Greenwald E, bukawski R, Harris J, Levin B, Gaynor E, Loutifi A, Kalser M, Barkin J, Benedetto P, Woolley P, Nauta R, Weaver D, Leichman L. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized phase III trial. J Clin Oncol 1989; 7:1419–1426.

    PubMed  CAS  Google Scholar 

  13. Poon M, O’Connell M, Wieand H, Krook J, Gerstner J, Tschetter L, Levitt R, Kardinal C, Mailliard J. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 1991;9:1967–1972.

    PubMed  CAS  Google Scholar 

  14. Nordic Gastrointestinal Tumor Adjuvant Therapy Group. Superiority of sequential methotrexate, fluorouracil, and leucovorin to fluorouracil alone in advanced sympromatic colorectal carcinoma: A randomized trial. J Clin Oncol 1989;7:1437–1446.

    Google Scholar 

  15. Valone F, Friedman M, Wittlinger P, Drakes T, Eisenberg P, Malec M, Hanningan J, Brown B Jr. Treatment of patients with advanced colorectal carcinomas with fluorouracil alone, high-dose leucovorin plus fluorouracil, or sequential methotrexate, fluorouracil, and leucovorin: A randomized trial of the Northern California Oncology Group. J Clin Oncol 1989;7:1427–1436.

    PubMed  CAS  Google Scholar 

  16. Doroshow J, Multhauf P, Leong L, Margolin K, Litchfield T, Akman S, Carr B, Bertrand M, Goldberg D, Blayney D, Odujinrin O, DeLap R, Shuster J, Newman E. Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J Clin Oncol 1990;8:491–501.

    PubMed  CAS  Google Scholar 

  17. Erlichman C, Fine S, Wang A, Elhakim T. A randomized trial of fluorouracil and folinic acid in patients with metastatic colorectal carcinoma. J Clin Oncol 1988;6:469–475.

    PubMed  CAS  Google Scholar 

  18. Poon MA, O’Connell MJ, Moertel CG, Wieand HS, Cullinan SA, Everson LK, Drook JE, Mailliard JA, Laurie JA, Tschetter LK, Wiesenfeld M. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. J Clin Oncol 1989;7:1407–1418.

    PubMed  CAS  Google Scholar 

  19. Buroker TR, O’Connell MJ, Wieand HS, Krook JE, Gerstner JB, Mailliard JA, Schaefer PL, Levitt R, Dardinal CG, Gesme DH Jr. Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer. J Clin Oncol 1994;1:14–20.

    Google Scholar 

  20. Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG. A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal cancer: A Mid-Atlantic Oncology Program study. J Clin Oncol 1989;7:425–432.

    PubMed  CAS  Google Scholar 

  21. Cunningham D, Zalcberg JR, Rath U, Olver I, Van Cutsem E, Svensson, C, Geitz JF, Harper P, Kerr D, Perez-Manja G, et al. Tomudex (ZD1694): Results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The Tomudex Colorectal Cancer Study Group. Eur J Cancer 1995;31A:1945–1954.

    Article  PubMed  CAS  Google Scholar 

  22. Zalcberg JR, Cunningham D, Van Cutsem E, Francois E, Schornagel J, Adenis A, Green M, Iveson A, Azab M. Seymour I. ZD1694. A novel thymidylate synthase inhibitor with substantial activity in the treatment of patients with advanced colorectal cancer. Tomudex Colorectal Study Group. J Clin Oncol 1996;14:716–721.

    PubMed  CAS  Google Scholar 

  23. Rinaidi DA, Burris HA, Dorr FA, Woodworth JR, Kuhn JG, Eckardt JR, Rodriguez G, Corso SW, Fields SM, Langley C, Clark G, Faries D, Lu P, Von Hoff DD. Initial phase levaluation of the novel thymidylate synthase inhibitor, LY231514, using the modified continual reassessment method for dose escalation. J Clin Oncol. 1995;13:2842–2850.

    Google Scholar 

  24. Bajetta E, Colleoni M, DiBartolomeo M, Buzzoni R, Bozzetti F, Doci R, Somma L, Cappuzzo F, Stampion GC, Guenzi A, Balant LP, Zilembo N, DiLeo A. Doxifluridine and leucovorin: An oral treatment combination in advanced colorectal cancer. J Clin Oncol 1995;13:2613–2619.

    PubMed  CAS  Google Scholar 

  25. Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugarman SM, Patt YZ, Jones DV Jr, Markowitz AB, Abbruzzese JL, Bready B, Levin B. Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 1994;12:2296–2300.

    PubMed  CAS  Google Scholar 

  26. Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP. A fixed-ratio combination of ruacil and ftorafur (UFT) with low dose leucovorin: An active oral regimen for advanced colorectal cancer. Cancer 1995;75:782–785.

    Article  PubMed  CAS  Google Scholar 

  27. Shimada Y, Yoshino M, Wakui A, Nakoo I, Futatsuki K, Sakata Y, Kambe M, Taguchi T, Ogawa N. CPT-11 Gastrointestinal Cancer Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993;11:909–913.

    PubMed  CAS  Google Scholar 

  28. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA III, Nelson J, Hilsenbeck SG, Rodriguez GI, Thurman AM, Smith LS, Eckhardt SG, Weiss GR, Elfring GL, Rinaldi DA, Schaaf LF, VanIIoff DD. Phase II trial of irinotecan in patients, with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128–1135.

    PubMed  CAS  Google Scholar 

  29. Sela S, Husain SR, Pearson JW, Longo DL, Rahman A. Reversal of multidrug resistance in human colon cancer cells expressing the human MDR-1 gene by liposomes in combination with monoclonal antibody or verapamil. J Natl Cancer Inst 1995;87:123–127.

    Article  PubMed  CAS  Google Scholar 

  30. Beck WT. Circumvention of multidrug resistance with anti-P-glycoprotein antibodies: Clinical potential or experimental artifact? J Natl Cancer Inst 1995;87:73–75.

    Article  PubMed  CAS  Google Scholar 

  31. Fagerberg J, Steinitz, M, Wigzell H, Askelof P, Mellstedt H. Human anti-idiotypic antibodies induced a humoral and cellular immune response against a colorectal carcinoma-associated antigen in patients. Proc Natl Acad Sci USA 1995; 92:4773–4777.

    Article  PubMed  CAS  Google Scholar 

  32. Fagerberg J, Hjelm AL, Ragnhammar P, Frodin JE, Wigzell H, Mellstedt H. Tumor regression in monoclonal antibodytreated patients corrclates with the presence of anti-idiotypereactive T lymphocytes. Cancer Res 1995;55;1824–1827.

    PubMed  CAS  Google Scholar 

  33. Buckley DT, Robins AR, Durrant LG. Clinical evidence that the human monoclonal anti-idiotypic antibody, 105AD7, delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas 1995;6:68–72.

    PubMed  CAS  Google Scholar 

  34. Moertel CG. Vaccine adjuvant therapy for colorectal cancer: “Very dramatic” or ho-hum? J Clin Oncol 1993;11:385–386.

    PubMed  CAS  Google Scholar 

  35. Hoover IIC Jr, Brandhorst JS, Peters LC, Surdyke MG, Takeshita Y, Madariaga J, Muenz LR, Hanna MG Jr. Adjuvant active specific immunotherapy for human colorectal cancer: 6,5-year median follow-up of a phase III prospectively randomized trial. J Clin Oncol 1993;11:390–399.

    PubMed  Google Scholar 

  36. Conry RM, LoBuglio AF; Loechel F, Moore SE, Sumerel LA, Barlow DL, Pike J, Curiel DT. A carcinoembryonic antigen polynucleotide vaccine for human clinical use. Cancer Gene Ther 1995;2:33–38.

    PubMed  CAS  Google Scholar 

  37. Adluri S, Helling F, Ogata S, Zhang S, Itzkowitz SH, Lloyd KO, Livingston PO. Immunogenicity of synthetic TF-KLH (keyhole limpet hemocyanin) and sTn-KLH conjugates in colorectal carcinoma patients. Cancer Immunol Immunother 1995;41:185–192.

    PubMed  CAS  Google Scholar 

  38. Chen SH, Chen XH, Wang Y, Kosai K, Finegold MJ, Rich SS, Woo SL. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA 1995; 92:2577–2581.

    Article  PubMed  CAS  Google Scholar 

  39. Trinh, QT, Austin EA, Murray DM, Knick VC, Huber BE. Enzyme/prodrug gene therapy: Comparison of cytosine deaminase/5-fluorocytosine versus thymidine kinase/ganciclovir enzyme/prodrug systems in a human colorectal carcinoma cell line. Cancer Res 1995;55:4808–4812.

    PubMed  CAS  Google Scholar 

  40. Moore M, Cripps C, DeGara C, Langer B, Pedersen J, Wong A, James K, Myles J, Iscoe N, Sargeant A. A phase III study of immediate versus delayed chemotherapy for asymptomatic advanced colorectal cancer, National Cancer Institute of Canada CTG trial CO.10, June 20, 1994.

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, McGill University, McIntyre Medical Sciences Building, 3655 Drummond, Suite 701, H3G 1Y6, Montreal, Quebec, Canada

    Brian Leyland-Jones M.D. & Susan Burdette-Radoux M.D.

Authors
  1. Brian Leyland-Jones M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan Burdette-Radoux M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Leyland-Jones, B., Burdette-Radoux, S. Management of hepatic metastases from colorectal cancer: Systemic chemotherapy. J Gastrointest Surg 1, 576–582 (1997). https://doi.org/10.1016/S1091-255X(97)80075-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1016/S1091-255X(97)80075-3

Keywords

Search

Navigation